Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Stay Tuned

<< Previous

Bullboard Posts

Next >>

Comment by crow27on Feb 11, 2021 11:03am

106 Views

Post# 32537648

RE:RE:RE:RE:Stay Tuned

Thats why the Crow is buying today. Many times a stock is a much better deal even though you pay a much higher price. The reason for that is is that the stock is de-risked. This deal with China basically removed all the fear that was in the stock at $3.50. People do not mind paying for de-risking.
This is a classic case of this with ATB. Big players will only buy when this happens. The gamblers buy before this happens and sometimes you win and most of the time you lose. This has now become a solid investment.
Just wait and see when the word NASDAQ listing is mentioned in the next NR.

<< Previous

Bullboard Posts

Next >>

Canadian government approves Glencore’s takeover of Teck’s coal business